Compare Crispr Therapeutics AG (CRSP) vs Western Union Co (WU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Western Union Co — how do they compare? Crispr Therapeutics AG trades at $49.94 (market cap $4.97B), while Western Union Co trades at $7.82 (market cap $2.46B). The key difference: Crispr Therapeutics AG is far larger — about 2× Western Union Co's market cap, and Western Union Co pays a 11.93% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | WU | |
|---|---|---|
Market Cap | $4.97B | $2.46B |
Sector | Health | Technology |
52-Week High | $76.78 | $10.28 |
52-Week Low | $44.34 | $7.04 |
Enterprise Value | $3.32B | $2.16B |
Dividend Yield | — | 11.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Western Union (WU) trades at $7.87, up 0.38% with a bullish technical signal. The stock shows attractive valuation with P/E of 5.79 and P/S of 0.63, supported by strong profitability metrics including 47.66% ROE. Recent earnings show mixed performance with Q1 2026 miss but Q3 and Q4 2025 beats. The company maintains strategic partnerships with Total Wireless and digital expansion initiatives, though revenue has declined from $4.5B in 2022 to $4.05B in 2025.
WU presents a value opportunity with deep valuation discounts but faces revenue headwinds and competitive pressures. The 11.5% dividend yield provides income support, though high debt levels and declining net income margins warrant caution. Analyst consensus remains mixed with 58% hold ratings, reflecting balanced risk-reward amid digital transformation efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →
